The risks of gastrointestinal adverse events with initiation of sodium polystyrene sulphonate

Sodium polystyrene sulphonate (SPS) has been widely used for hyperkalemia management in chronic kidney disease (CKD). However, data on its safety are scarce and ambiguous. A retrospective cohort study based on the nationwide Swedish Renal Registry examined patterns of use and adverse events associated to SPS initiation during follow-up. 3690 patients initiated SPS during follow-up, of whom 59% took SPS chronically. SPS initiation was associated with a higher incidence of both severe (mainly attributed to ulcers and perforations) events, particularly in those receiving per label doses, and minor gastrointestinal events, regardless of dose.

Read the full article here: https://academic.oup.com/ndt/article/35/9/1518/5543535